The result Harmony outcomes (Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease) with albiglutide, a long-acting formulation of GLP1-RA, slightly reduced the mean systolic BP in the albiglutide group compared with the placebo group, and BP difference was similar between 8 and 16 months (-0.65 and -0.67 mm Hg at 8 months and 16 months) [71]. This evidence concerns the gene GLP1R and cardiovascular disorder.